



## Guaranteed new share issue with preferential rights

- A new share issue of 1,511 MSEK with preferential rights for the shareholders of Meda
- Each shareholder is offered to subscribe for one (1) new share for every six (6) shares held at the record date
- The subscription price is 35 SEK per share
- Term of subscription runs between November 10 and November 24, 2008
- The share issue is guaranteed in full through a subscription undertaking issued by Stena Sessan Rederi AB and Stena Jutlandica AB and through a guarantee commitment issued by Stena AB (publ).

### Background and rationale

With reference to Meda's acquisition of Valeant Pharmaceuticals International's pharmaceutical business in Western and Eastern Europe, the acquisition of a product portfolio from Roche and in order to establish preparedness for further business opportunities, the board of directors of the company has decided, subject to the approval of the extraordinary general meeting, upon a new issue of shares with preferential rights for Meda's shareholders. The share issue will generate 1,511 MSEK to the company (prior to transaction costs).

## Share Issue Terms

The board of directors of Meda has decided to, subject to the approval of the extra general meeting on October 31, 2008, implement a share issue with preferential rights for the shareholders. The share issue will comprise a total of a maximum of 43 177 580 shares. Six (6) existing shares at the record date entitles to subscription of one (1) new share. Shares that have not been subscribed pursuant to preferential rights will be offered to shareholders who applied to subscribe for shares without preferential right. The subscription price shall be 35.00 SEK per share. The subscription period runs between November 10 to November 24, 2008. The share issue will, upon full subscription, lead to an increase in the share capital of Meda to 302 243 065 SEK. Meda will after the issue of shares have a maximum of 302 243 065 shares.

## Guarantee Commitment and Subscription Undertaking

The largest shareholder in Meda, Stena Sessan Rederi AB, who together with a subsidiary represents 25.9 percent of the shares and votes in the Company, has declared its support for the decision made by the board of directors and have undertaken to vote in favour of the approval of the decision at the extraordinary general meeting and in addition thereto to subscribe for, or see to the subscription of, its entire preferential right in the share issue. Further, Stena AB (publ) has, to the above stated subscription price, undertaken to finally subscribe for shares that have not been subscribed and paid for by the shareholders. The guarantee is issued on customary terms.

## Preliminary timetable for the share issue

Extra general meeting of the shareholders	<i>October 31, 2008</i>
The share is traded with right to participate in the new issue of shares	<i>October 31, 2008</i>
The share is traded without right to participate in the new issue of shares	<i>November 3, 2008</i>
The record date for participating in the issue of shares, i.e. the shareholders that are registered as shareholders in the share register of Meda at that day will obtain subscription rights in order to participate in the new issue of shares.	<i>November 5, 2008</i>
The prospectus will be made public	<i>Approx. November 5, 2008</i>
Trade with subscription rights	<i>November 10 – November 19, 2008</i>

Trade with paid and subscribed shares

*November 10, 2008 - until the issue of shares has been registered with the Swedish Companies Registration Office*

Subscription period for the new shares

*November 10 – November 24, 2008*

For additional information, Meda is referring to the prospectus which will be prepared for the share issue.

### **Financial Advisors**

Danske Markets is the financial advisor of Meda in connection with the issue of shares.

---

### **For more information, please contact:**

Anders Larnholt, Vice President Investor Relations, tel. +46 709 458 878

---

**MEDA AB (publ)** is a leading international specialty pharma company. The company specialises in marketing and pharmaceutical development in late clinical stage. Acquisitions and long-term partnerships are fundamental factors that drive the company's strategy. Meda is represented by its own organisations in about 40 countries. Meda's products are sold in 120 countries worldwide. The Meda share is listed under Large Cap on the OMX Nordic Stock Exchange. Find out more, visit [www.meda.se](http://www.meda.se).

*The publication or distribution of this press release may in certain jurisdictions be subject to restrictions by law and persons in such jurisdictions where this press release has been made public or distributed should inform themselves about such restrictions and act accordingly.*

*This press release may not be announced, published or distributed, directly or indirectly, to or in the United States of America, Canada, Australia, Hong Kong, Japan or in any other country where such measure wholly or partly is subject to restrictions by law. The information in this press release may not be forwarded, reproduced or shown in way that is in conflict with such restrictions. Failure to comply with this instruction may constitute a violation of the United States Securities Act of 1933 ("Securities Act") or applicable laws in other jurisdictions.*

*Nothing in this press release shall be deemed to constitute an invitation or an offer to invest, subscribe or otherwise deal with shares, subscription right or other securities in Meda. The invitation to relevant persons to subscribe for shares in Meda will only be made in the prospectus which Meda is intending to make public around November 5, 2008. The prospectus will inter alia contain accounting records and information about the board directors and the auditor of Meda.*

*Neither the subscription rights, nor the paid and subscribed shares or the new shares will be registered pursuant to the Securities Act or to any provincial law in Canada and may not be transferred or offered for sale in the USA or Canada, or to a person domiciled in such state or for such persons account other in such cases, where registration is not required pursuant to the Securities Act or any provincial law in Canada.*

*Meda is obliged to make this information public according the Financial Markets Act and the Financial Instruments Trading Act (Sw: lagen om värdepappersmarknaden and lagen om handel med finansiella instrument). The information has been submitted for publication on October 14, 2008, at 8.00 am.*